MedTrace Logo

FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump

NCT03977727 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-09-29

Study results available
· View outcomes & findings →

Summary

This is an exploratory, single-center, randomized, open label, active-controlled, complete cross-over trial comparing safety and efficacy of Fiasp® versus NovoLog® when used in the Medtronic MiniMed 670G system in subjects with T1DM.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

DRUG

Fiasp®

Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system

DRUG

Novolog®

Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system

DEVICE

670G hybrid closed loop continuous subcutaneous insulin infusion system

CSII

Sponsors & Collaborators

  • Texas Diabetes & Endocrinology, P.A.

    lead OTHER

Principal Investigators

  • Thomas Blevins, MD · Texas Diabetes & Endocrinology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-11
Primary Completion
2020-03-09
Completion
2020-04-20
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03977727 on ClinicalTrials.gov